

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Brii Biosciences Limited
騰盛博藥生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2137)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE

This announcement is made by the board of directors (the “**Board**”) of Brii Biosciences Limited (the “**Company**”) on a voluntary basis.

The Board is pleased to announce that today the Company presented new data from a Phase 2 randomized, double-blind and placebo-controlled trial of BRII-835 (VIR-2218) in Chinese patients with chronic hepatitis B virus (“**HBV**”) infection, at the 31st Conference of Asian Pacific Association for the Study of the Liver 2022 which takes place virtually from March 30, 2022 to April 3, 2022 in Seoul, South Korea.

The data demonstrates that BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid (“**siRNA**”) that mediates ribonucleic acid interference (“**RNAi**”), results in dose-dependent reduction in hepatitis B surface antigen (“**HBsAg**”) in Chinese patients with chronic HBV infection who received two doses of BRII-835 (VIR-2218). Similar HBsAg reductions were observed in both hepatitis B e antigen negative (“**HBeAg-**”) and hepatitis B e antigen positive (“**HBeAg+**”) patients. In addition, BRII-835 (VIR-2218) was well-tolerated, with all treatment emergent adverse events reported as mild or moderate, and no clinically significant alanine transaminase elevations were observed.

“The dose-dependent reduction in serum HBsAg observed in both HBeAg- and HBeAg+ Chinese chronic HBV patients in this trial after two doses of BRII-835 (VIR-2218) is consistent with previous findings demonstrated in other racial/ethnic groups,” said Dr. Jidong Jia, who is the Professor of Medicine at the Liver Research Centre, Beijing Friendship Hospital, Capital Medical University in Beijing, China. “Supported by these data, we believe that novel agents like BRII-835 (VIR-2218) that effectively reduce the high HBV antigen burden has the potential to be the cornerstone of functional cure regimens for patients with chronic HBV infection, thereby facilitating the elimination of this major global public health threat.”

“As part of our goal to develop a functional cure for chronic HBV, we are pleased that the data from this trial continue to support the potential of siRNA as the backbone of combination treatment regimens that are being evaluated in several ongoing trials,” said Dr. Li Yan, the Chief Medical Officer of the Company. “We look forward to seeing more data later this year from these trials in which BRII-835 (VIR-2218) is being investigated in combination with other agents.”

Abstract Number: L-OP-1324

Oral Presentation Title: Safety and antiviral activity of two monthly administrations of BRII-835 (VIR-2218), an X-targeting RNAi therapeutic, in Chinese patients with chronic HBV infection

Presenter: Dr. Jidong Jia, M.D., Ph.D., Professor of Medicine at Capital Medical University and the Director of the Liver Research Centre at Beijing Friendship Hospital in Beijing, China

- BRII-835 (VIR-2218) was well-tolerated in 16 virally-suppressed Chinese patients with non-cirrhotic chronic HBV infection assigned to receive two doses of monthly subcutaneous injection of BRII-835
- 12 weeks post last dose, the mean reductions in HBsAg observed in patients who received 50mg and 100mg doses of BRII-835 were $1.02 \log_{10}$ IU/mL and $1.22 \log_{10}$ IU/mL for HBeAg- patients and $0.70 \log_{10}$ IU/mL and $1.15 \log_{10}$ IU/mL for HBeAg+ patients, respectively
- In all patients achieving HBsAg decline $> 1 \log_{10}$ IU/mL at 12 weeks post last dose, serum HBsAg remained below baseline through 48 weeks

At present, BRII-835 (VIR-2218) is being investigated in three additional Phase 2 studies, sponsored by the Company and Vir Biotechnology, Inc., respectively, in combinations with BRII-179 (a recombinant therapeutic vaccine), pegylated interferon-alpha and/or VIR-3434 (a monoclonal antibody targeting HBV) as a functional cure regimen for chronic HBV infection.

Cautionary Statement: There is no assurance that BRII-835 (VIR-2218) will ultimately be successfully developed or marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, March 31, 2022

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Mr. Yongqing Luo as executive directors; Mr. Robert Taylor Nelsen and Dr. Axel Bouchon as non-executive directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui and Mr. Gregg Huber Alton as independent non-executive directors.